B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules

Neil Elliot Kay, N. D. Bone, R. C. Tschumper, K. H. Howell, S. M. Geyer, G. W. Dewald, C. A. Hanson, Diane F Jelinek

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Initial work has shown that clonal B cells from B-chronic lymphocytic leukemia (B-CLL) are able to synthesize pro-angiogenic molecules. In this study, our goal was to study the spectrum of angiogenic factors and receptors expressed in the CLL B cell. We used ELISA assays to determine the levels of basic fibroblast growth factors (bFGF), vascular endothelial growth factor (VEGF), endostatin, interferon-α (IFN-α) and thrombospondin-1 (TSP-1) secreted into culture medium by purified CLL B cells. These data demonstrated that CLL B cells spontaneously secrete a variety of pro- and anti-angiogenic factors, including bFGF (23.9 pg/ml ± 7.9; mean ± s.e.m.), VEGF (12.5 pg/ml ± 2.3) and TSP-1 (1.9 ng/ml ± 0.3). Out of these three factors, CLL B cells consistently secreted bFGF and TSP-1, while VEGF was expressed in approximately two-thirds of CLL patients. Of interest, hypoxic conditions dramatically upregulated VEGF expression at both the mRNA and protein levels. We also employed ribonuclease protection assays to assay CLL B cell expression of a variety of other angiogenesis-related molecules. These analyses revealed that CLL B cells consistently express mRNA for VEGF receptor 1 (VEGFR1), thrombin receptor, endoglin, and angiopoietin. Further analysis of VEGFR expression by RT-PCR revealed that CLL B cells expressed both VEGFR1 mRNA and VEGFR2 mRNA. In summary, these data collectively indicate that CLL B cells express both pro- and anti-angiogenic molecules and several vascular factor receptors. Because of the co-expression of angiogenic molecules and receptors for some of these molecules, these data suggest that the biology of the leukemic cells may also be directly impacted by angiogenic factors as a result of autocrine pathways of stimulation.

Original languageEnglish (US)
Pages (from-to)911-919
Number of pages9
JournalLeukemia
Volume16
Issue number5
DOIs
StatePublished - 2002

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Thrombospondin 1
Vascular Endothelial Growth Factor A
Angiogenesis Inducing Agents
Fibroblast Growth Factor 2
Messenger RNA
Angiopoietins
Endostatins
B-Cell Leukemia
Thrombin Receptors
Vascular Endothelial Growth Factor Receptor-1
Fibroblast Growth Factor 1
Vascular Endothelial Growth Factor Receptor
Ribonucleases
Interferons
Cell Biology
Culture Media
Enzyme-Linked Immunosorbent Assay
Polymerase Chain Reaction

Keywords

  • B-CLL
  • TSP-1
  • Vascular factors
  • VEGF

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. / Kay, Neil Elliot; Bone, N. D.; Tschumper, R. C.; Howell, K. H.; Geyer, S. M.; Dewald, G. W.; Hanson, C. A.; Jelinek, Diane F.

In: Leukemia, Vol. 16, No. 5, 2002, p. 911-919.

Research output: Contribution to journalArticle

Kay, NE, Bone, ND, Tschumper, RC, Howell, KH, Geyer, SM, Dewald, GW, Hanson, CA & Jelinek, DF 2002, 'B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules', Leukemia, vol. 16, no. 5, pp. 911-919. https://doi.org/10.1038/sj.leu.2402467
Kay, Neil Elliot ; Bone, N. D. ; Tschumper, R. C. ; Howell, K. H. ; Geyer, S. M. ; Dewald, G. W. ; Hanson, C. A. ; Jelinek, Diane F. / B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. In: Leukemia. 2002 ; Vol. 16, No. 5. pp. 911-919.
@article{2cf16d5a30354a90ad20f04bde460cae,
title = "B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules",
abstract = "Initial work has shown that clonal B cells from B-chronic lymphocytic leukemia (B-CLL) are able to synthesize pro-angiogenic molecules. In this study, our goal was to study the spectrum of angiogenic factors and receptors expressed in the CLL B cell. We used ELISA assays to determine the levels of basic fibroblast growth factors (bFGF), vascular endothelial growth factor (VEGF), endostatin, interferon-α (IFN-α) and thrombospondin-1 (TSP-1) secreted into culture medium by purified CLL B cells. These data demonstrated that CLL B cells spontaneously secrete a variety of pro- and anti-angiogenic factors, including bFGF (23.9 pg/ml ± 7.9; mean ± s.e.m.), VEGF (12.5 pg/ml ± 2.3) and TSP-1 (1.9 ng/ml ± 0.3). Out of these three factors, CLL B cells consistently secreted bFGF and TSP-1, while VEGF was expressed in approximately two-thirds of CLL patients. Of interest, hypoxic conditions dramatically upregulated VEGF expression at both the mRNA and protein levels. We also employed ribonuclease protection assays to assay CLL B cell expression of a variety of other angiogenesis-related molecules. These analyses revealed that CLL B cells consistently express mRNA for VEGF receptor 1 (VEGFR1), thrombin receptor, endoglin, and angiopoietin. Further analysis of VEGFR expression by RT-PCR revealed that CLL B cells expressed both VEGFR1 mRNA and VEGFR2 mRNA. In summary, these data collectively indicate that CLL B cells express both pro- and anti-angiogenic molecules and several vascular factor receptors. Because of the co-expression of angiogenic molecules and receptors for some of these molecules, these data suggest that the biology of the leukemic cells may also be directly impacted by angiogenic factors as a result of autocrine pathways of stimulation.",
keywords = "B-CLL, TSP-1, Vascular factors, VEGF",
author = "Kay, {Neil Elliot} and Bone, {N. D.} and Tschumper, {R. C.} and Howell, {K. H.} and Geyer, {S. M.} and Dewald, {G. W.} and Hanson, {C. A.} and Jelinek, {Diane F}",
year = "2002",
doi = "10.1038/sj.leu.2402467",
language = "English (US)",
volume = "16",
pages = "911--919",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules

AU - Kay, Neil Elliot

AU - Bone, N. D.

AU - Tschumper, R. C.

AU - Howell, K. H.

AU - Geyer, S. M.

AU - Dewald, G. W.

AU - Hanson, C. A.

AU - Jelinek, Diane F

PY - 2002

Y1 - 2002

N2 - Initial work has shown that clonal B cells from B-chronic lymphocytic leukemia (B-CLL) are able to synthesize pro-angiogenic molecules. In this study, our goal was to study the spectrum of angiogenic factors and receptors expressed in the CLL B cell. We used ELISA assays to determine the levels of basic fibroblast growth factors (bFGF), vascular endothelial growth factor (VEGF), endostatin, interferon-α (IFN-α) and thrombospondin-1 (TSP-1) secreted into culture medium by purified CLL B cells. These data demonstrated that CLL B cells spontaneously secrete a variety of pro- and anti-angiogenic factors, including bFGF (23.9 pg/ml ± 7.9; mean ± s.e.m.), VEGF (12.5 pg/ml ± 2.3) and TSP-1 (1.9 ng/ml ± 0.3). Out of these three factors, CLL B cells consistently secreted bFGF and TSP-1, while VEGF was expressed in approximately two-thirds of CLL patients. Of interest, hypoxic conditions dramatically upregulated VEGF expression at both the mRNA and protein levels. We also employed ribonuclease protection assays to assay CLL B cell expression of a variety of other angiogenesis-related molecules. These analyses revealed that CLL B cells consistently express mRNA for VEGF receptor 1 (VEGFR1), thrombin receptor, endoglin, and angiopoietin. Further analysis of VEGFR expression by RT-PCR revealed that CLL B cells expressed both VEGFR1 mRNA and VEGFR2 mRNA. In summary, these data collectively indicate that CLL B cells express both pro- and anti-angiogenic molecules and several vascular factor receptors. Because of the co-expression of angiogenic molecules and receptors for some of these molecules, these data suggest that the biology of the leukemic cells may also be directly impacted by angiogenic factors as a result of autocrine pathways of stimulation.

AB - Initial work has shown that clonal B cells from B-chronic lymphocytic leukemia (B-CLL) are able to synthesize pro-angiogenic molecules. In this study, our goal was to study the spectrum of angiogenic factors and receptors expressed in the CLL B cell. We used ELISA assays to determine the levels of basic fibroblast growth factors (bFGF), vascular endothelial growth factor (VEGF), endostatin, interferon-α (IFN-α) and thrombospondin-1 (TSP-1) secreted into culture medium by purified CLL B cells. These data demonstrated that CLL B cells spontaneously secrete a variety of pro- and anti-angiogenic factors, including bFGF (23.9 pg/ml ± 7.9; mean ± s.e.m.), VEGF (12.5 pg/ml ± 2.3) and TSP-1 (1.9 ng/ml ± 0.3). Out of these three factors, CLL B cells consistently secreted bFGF and TSP-1, while VEGF was expressed in approximately two-thirds of CLL patients. Of interest, hypoxic conditions dramatically upregulated VEGF expression at both the mRNA and protein levels. We also employed ribonuclease protection assays to assay CLL B cell expression of a variety of other angiogenesis-related molecules. These analyses revealed that CLL B cells consistently express mRNA for VEGF receptor 1 (VEGFR1), thrombin receptor, endoglin, and angiopoietin. Further analysis of VEGFR expression by RT-PCR revealed that CLL B cells expressed both VEGFR1 mRNA and VEGFR2 mRNA. In summary, these data collectively indicate that CLL B cells express both pro- and anti-angiogenic molecules and several vascular factor receptors. Because of the co-expression of angiogenic molecules and receptors for some of these molecules, these data suggest that the biology of the leukemic cells may also be directly impacted by angiogenic factors as a result of autocrine pathways of stimulation.

KW - B-CLL

KW - TSP-1

KW - Vascular factors

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0036099930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036099930&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2402467

DO - 10.1038/sj.leu.2402467

M3 - Article

VL - 16

SP - 911

EP - 919

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -